BUZZ - Vaxcyte shares soar following successful late-stage clinical trial for pneumococcal vaccine
路透社2026/10/05 10:26October 5 – Vaxcyte (PCVX.O) shares surged 26% pre-market to $71.17. Vaxcyte announced that its 31-valent pneumococcal vaccine VAX-31 met all primary endpoints in a late-stage clinical trial, and generated immune responses comparable to or stronger than Pfizer’s Prevnar 20 and Merck’s Capvaxive. The safety and tolerability of the vaccine were similar to existing vaccines. Vaxcyte expects results from two additional late-stage clinical trials in the first half of 2027, and plans to submit a marketing application to the FDA in the first half of 2028. As of the previous trading session’s close, the stock had risen 22.4% year-to-date.
October 5 - ** Vaxcyte (PCVX.O) shares surged 26% in pre-market trading to $71.17
** Vaxcyte stated that its 31-valent pneumonia vaccine VAX-31 met all primary endpoints in a late-stage clinical trial (link) and generated an immune response comparable to or stronger than that of Pfizer's PFE.N Prevnar 20 and Merck's MRK.N Capvaxive
** The safety and tolerability of the vaccine were comparable to existing vaccines
** Vaxcyte expects to obtain results from two additional late-stage clinical trials in the first half of 2027 and plans to submit a marketing application to the FDA in the first half of 2028
** As of the close of the previous trading day, the stock had risen 22.4% year-to-date
(To facilitate non-English speakers, Reuters provides automated translations of its reports into several other languages. Automated translation may be inaccurate or may fail to capture the intended meaning, and Reuters makes no guarantee regarding the accuracy of the translated text. Automated translation is provided solely for the convenience of readers. Reuters accepts no liability for any damages or losses arising from the use of this automated translation function.)
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
BUZZ - US Stock Market Dynamics - RXO, Harley-Davidson, Vistra
Search string for querying individual stock trends in the workspace: STXBZ "Today's Outlook" newsletter: https://refini.tv/3LI4BU7 "Morning News Brief" newsletter: https://refini.tv/3dKUyB8 Reuters, October 5 - On Monday, U.S. stock index futures edged lower as tech stocks retreated after reaching record highs. As Treasury yields and oil prices remain elevated, investors are seeking new clues about the direction of monetary policy. .N ** RXO RXO.N: Market focus — RXO shares rose following C.H. Robinson's announcement of a 5.8 billions USD acquisition plan nL6N45R0N4 ** Harley-Davidson HOG.N: Market focus — Citi upgraded Harley-Davidson to "Buy," shares climbed nL6N45R0M3 ** GEO Group GEO.N: Spotlight — GEO gained as it sold ICE facilities for 950 millions USD and expanded its stock buyback nL6N45R0MR ** Vistra VST.N: Spotlight — Vistra rallied as it was reportedly set to receive a 4.2 billions USD U.S. nuclear loan nL4N45R0L8 ** Vaxcyte PCVX.O: Spotlight — Vaxcyte surged after positive late-stage clinical trial data for its pneumococcal vaccine nL4N45R0K0 ** Estée Lauder EL.N: Spotlight — Barclays upgraded Estée Lauder to "Overweight," shares advanced nL6N45R0HX ** PTC PTC.O: Spotlight — Schneider Electric agreed to acquire PTC for 22.6 billions USD, shares jumped nL6N45R0HV (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Since automatic translation may contain errors or fail to convey the required context, Reuters does not guarantee the accuracy of automatically translated texts and provides them solely for readers’ convenience. Reuters accepts no liability for any damages or losses arising from the use of automated translation features.)
BUZZ-Alector stock surges after agreement with Genentech on an experimental Parkinson's disease drug
October 5 - The stock price of pharmaceutical company Alector (ALEC.O) surged by 44.20% in pre-market trading, reaching $2.61. The company has entered into a global licensing agreement with Genentech for AL050, an experimental drug developed by ALEC for the treatment of Parkinson's disease. ALEC has granted Genentech the exclusive worldwide rights to develop and commercialize AL050. According to ALEC, the agreement will bring an upfront payment of $100 million and may result in milestone payments of up to $1.17 billion by 2029. The company retains ownership of its ABC technology platform for developing therapies for neurodegenerative diseases, as well as all rights to use the platform in its research and development pipeline. As of the close of the previous trading day, ALEC's stock price had risen by 16.03%. (For the convenience of non-English speakers, Reuters automatically translates its reports into several other languages. Due to possible errors in automation or lack of context, Reuters does not guarantee the accuracy of the automated translation, which is provided solely for the convenience of readers. Reuters assumes no responsibility for any damage or loss caused by the use of the automated translation.)
How Far Can 12 Straight Wins Take a Trader Who Is Still Down $22.8 Million?
Crypto prices
More
